Contribute Try STAT+ Today

On the evening that would jolt the global traffic of cancer treatments, David Kim was driving his baby daughter around, trying to get her to sleep. Bedtime was rough: Only the smooth motion of a car could get her to doze off. So Kim was playing dad-chauffeur, with the radio on low, when he heard that President Trump was banning travel between the United States and Europe.

His mind instantly churned with questions. If movement was comforting to his daughter, for his clients, it was a necessity. At the time, he was director of global supply chain for Kite Pharma, and the firm’s new factory in the Netherlands was still four months from ready. That meant that the treatment hundreds of European cancer patients were relying on was transatlantic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.